EDGAR Filing Documents for 0000891293-18-000018

Form 8-K - Current report:

SEC Accession No. 0000891293-18-000018

Filing Date

2018-01-24

Accepted

2018-01-24 16:32:04

Documents

Period of Report

2018-01-24

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	omm_us-76083654x6xctix8xks.htm	8-K	55044
2	EXHIBIT 2.1	cti-reincorporationmergera.htm	EX-2.1	46583
3	EXHIBIT 3.1	delawarecertificateofincor.htm	EX-3.1	170395
4	EXHIBIT 3.2	delawarebylaws.htm	EX-3.2	130470
5	EXHIBIT 10.1	formofindemnificationagree.htm	EX-10.1	103732
	Complete submission text file	0000891293-18-000018.txt		507679

Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121

Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100

CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)